TY - JOUR
T1 - Immunotherapy as a treatment strategy in advanced stage and recurrent endometrial cancer
T2 - review of current phase III immunotherapy clinical trials
AU - Eskander, Ramez N.
AU - Powell, Matthew A.
N1 - Publisher Copyright:
© The Author(s), 2021.
PY - 2021
Y1 - 2021
N2 - The treatment of advanced stage, metastatic or recurrent endometrial cancer remains a clinically difficult scenario. Although combination carboplatin and paclitaxel is an effective standard-of-care regimen, alternate strategies have shown promise, particularly in biomarker select populations. In an effort to improve oncologic outcomes, investigators are exploring novel immunotherapy combinations. In this review, we discuss the clinical rationale and design of current phase III immuno-oncology clinical trials in patients with advanced stage or recurrent endometrial cancer.
AB - The treatment of advanced stage, metastatic or recurrent endometrial cancer remains a clinically difficult scenario. Although combination carboplatin and paclitaxel is an effective standard-of-care regimen, alternate strategies have shown promise, particularly in biomarker select populations. In an effort to improve oncologic outcomes, investigators are exploring novel immunotherapy combinations. In this review, we discuss the clinical rationale and design of current phase III immuno-oncology clinical trials in patients with advanced stage or recurrent endometrial cancer.
KW - antiangiogenic therapy
KW - chemotherapy
KW - combination therapy
KW - endometrial cancer
KW - immune checkpoint inhibition
KW - immunotherapy
KW - tumor mutational burden
UR - http://www.scopus.com/inward/record.url?scp=85102772833&partnerID=8YFLogxK
U2 - 10.1177/17588359211001199
DO - 10.1177/17588359211001199
M3 - Review article
C2 - 33796152
AN - SCOPUS:85102772833
SN - 1758-8340
VL - 13
JO - Therapeutic Advances in Medical Oncology
JF - Therapeutic Advances in Medical Oncology
ER -